Value of Combined PET Imaging with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [<sup>177</sup>Lu]Lu-PSMA-617 RLT

Value of Combined PET Imaging with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [<sup>177</sup>Lu]Lu-PSMA-617 RLT

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [<sup>18</sup>F]FDG and [&...

Full description

Bibliographic Details
Main Authors: Fadi Khreish, Kalle Ribbat, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Mathias Schreckenberger, Samer Ezziddin, Florian Rosar
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
radioligand therapy
PSMA
FDG
PET/CT
mismatch
metastatic castration-resistant prostate cancer
Online Access:https://www.mdpi.com/2072-6694/13/16/4134

Internet

https://www.mdpi.com/2072-6694/13/16/4134

Similar Items